Clinigen Group plc Annual Financial Report (4580N)
30 Septiembre 2021 - 1:59AM
UK Regulatory
TIDMCLIN
RNS Number : 4580N
Clinigen Group plc
30 September 2021
30(th) September 2021
Posting of Annual Report and Accounts and
arrangements for AGM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the
global pharmaceutical Services and Products company, announces that
its Annual Report and Accounts for the year ended 30 June 2021 is
now available on the Group's website at www.clinigengroup.com and
confirms the date and location for its Annual General Meeting
('AGM').
The Group will hold its AGM on Wednesday, 24 November 2021 at
10.00am GMT at 85 Gresham Street, London EC2V 7NQ. A hard copy of
the Annual Report will be mailed to shareholders later today.
The arrangements for the AGM are as follows:
Shareholders are able to attend the AGM in person this year.
Those intending to attend the AGM are asked to register their
intention by emailing agm@clinigengroup.com with 'AGM 2021 -
attendance' in the heading. However, at the time of writing it is
uncertain what regulations or public health guidance may be in
place at the time of the AGM and therefore the Board strongly
encourages shareholders to submit a proxy vote in advance of the
AGM and to appoint the Chairman of the meeting as their proxy,
rather than a named person who, if circumstances change, may not be
able to attend the meeting. Please refer to the instructions in the
Form of Proxy, which has been distributed with the Annual Report
and Accounts. We will continue to closely monitor any developments
in public health guidance and legislation issued by the UK
Government in relation to Covid-19. Should it become necessary or
appropriate to revise the current arrangements for the AGM, details
of any such changes will be made available on our website and via a
regulatory information service announcement.
The Company will upload a presentation to shareholders by the
Chief Executive Officer, Shaun Chilton, on the business of the
Clinigen Group and its performance over the last 12 months to
https://www.clinigengroup.com/investors/shareholder-services/agm .
The presentation will be uploaded no later than 12 November 2021.
The AGM will focus on the formal business of the meeting as set out
in the Notice of AGM.
Should any shareholder have questions they wish to ask, they
should email agm@clinigengroup.com with 'AGM 2021' in the heading.
The Company will collate the answers to the questions received and
upload them to https://www.clinigengroup.com/investors/
shareholder-services/agm following the publication of the results
of the AGM or, if more appropriate, reply to the questioner
directly . Questions must be received no later than 10.00 a.m. on
Monday, 22 November 2021.
- Ends -
Contact details
Clinigen Group plc +44 (0) 1283 495010
Rob Fox, VP Investor Relations and Corporate investors@clinigengroup.com
Development
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260
& Joint Broker 1000
James Black / Garry Levin / Freddie Barnfield Clinigen@Numis.com
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653
4000
Marcus Jackson / Elliot Thomas
Consilium Strategic Communications Tel: +44 (0) 20 3709
Mary-Jane Elliott / Matthew Cole / Jessica 5700 Clinigen@consilium-comms.com
Hodgson
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist
pharmaceutical services and products platform focused on providing
ethical access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time. The Group operates
from sites in North America, Europe, Africa and the Asia
Pacific.
Clinigen has more than 1,000 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 34 of the top 50 pharmaceutical companies; interacting
with over 5,000 hospitals across more than 120 countries.
For more information on Clinigen, please visit
http://www.clinigen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSUKOWRABUKUAR
(END) Dow Jones Newswires
September 30, 2021 02:59 ET (06:59 GMT)
Clinigen (LSE:CLIN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Clinigen (LSE:CLIN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024